Skip to main content
. 2021 Apr;12(Suppl 1):S242–S258. doi: 10.21037/jgo-20-257

Table 2. Adverse events.

Studies CRC patients Evaluated patients Total PIPAC-OX CTCAE
1–2 3 4 5
Siebert [2019] (13) 2 2 5 ns ns 2 ns
Katdare [2019] (14) 3 3 3 1 0 0 0
Demtröder [2016] (15) 17 17 42 25 4 0 0
Somashekhar [2019] (16) 1 1 3 0 0 0 0

CRC, colorectal cancer; PIPAC-OX, pressurized intraperitoneal aerosol chemotherapy with oxaliplatin; CTCAE, Common Terminology Criteria for Adverse Events; ns, not shown.